BRIEF—New mRNA collaboration for CRISPR, Casebia and CureVac

A new collaboration has been entered into by New York-listed CRISPR Therapeutics, Casebia Therapeutics and CureVac AG.

In return for an undisclosed upfront payment, research funding and potential milestone and royalty payments, CureVac will develop novel Cas9 mRNA constructs with improved properties for gene editing applications.

Under the terms of the deal, CRISPR Therapeutics and Casebia have obtained an exclusive license to the improved constructs for use in three of their in vivo gene-editing programs in liver diseases.

CureVac will also provide mRNA manufacturing through clinical development and commercialization of the three programs.